Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Portfolio Pulse from
Jaguar Health has received regulatory clearance in Germany and Italy for a Phase 2 study of crofelemer, a plant-based drug, for Short Bowel Syndrome with Intestinal Failure (SBS-IF). The study is part of five clinical efforts for rare diseases, with results expected in H1 2025.
February 19, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's crofelemer has received regulatory clearance in Germany and Italy for a Phase 2 study targeting SBS-IF. This development is part of broader clinical efforts for rare diseases, with potential results in H1 2025.
The regulatory clearance in Germany and Italy for the Phase 2 study of crofelemer is a positive development for Jaguar Health. It indicates progress in their clinical efforts and could lead to future market opportunities if the trials are successful. The Orphan-Drug Designation by the FDA and EMA further supports the potential significance of this drug in treating rare diseases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100